ERBB2 and breast cancer: Furthermore, our utilization of both the HMLE and BT474 models of Her2+ breast cancer clearly demonstrate that enhanced FGFR1 expression when in the presence of FGF ligand is sufficient to facilitate resistance to Lapatinib treatment.